PAGE: IPM BioMe Biobank

The Institute for Personalized Medicine (IPM) BioMe Biobank is a consented, EMR-linked medical care setting biorepository of the Mount Sinai Medical Center (MSMC) drawing from a population of over 70,000 inpatients and 800,000 outpatient visits annually. MSMC serves diverse local communities of upper Manhattan, including Central Harlem (86% African American), East Harlem (88% Hispanic Latino), and Upper East Side (88% Caucasian/white) with broad health disparities. IPM BioMe Biobank populations include 28% African American, 38% Hispanic Latino predominantly of Caribbean origin, 23% Caucasian/White. IPM BioMe Biobank disease burden is reflective of health disparities with broad public health impact. Biobank operations are fully integrated in clinical care processes, including direct recruitment from clinical sites waiting areas and phlebotomy stations by dedicated Biobank recruiters independent of clinical care providers, prior to or following a clinician standard of care visit. Recruitment currently occurs at a broad spectrum of over 30 clinical care sites. This study is part of the Population Architecture using Genomics and Epidemiology (PAGE) study (phs000356). ]]>
Study participants of self-reported European Ancestry were not included in the ISMMS PAGE II contribution.]]>
2007 IPM BioMe Biobank starts recruitment at the Mount Sinai Medical Center 2010 December: Almost 3,000 BioMe participants (Africa, European and Hispanic ancestry) were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 2011 August: IPM BioMe Biobank joins the eMERGE II Network 2012 November: A total of 23,000 participants have been recruited 2012 December: An additional ~13,000 BioMe participants were genotyped using the Illumina HumanOmniExpress BeadChip and the ExomeChip 2013 June: IPM BioMe Biobank joins the PAGE II Network 2015 January: A total of 33,000 participants have been recruited and recruitment continues. ]]>